Completed PHASE3 INTERVENTIONAL 2-arm NCT01724450

Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity (Ceccy)

Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.

Sponsor: Hospital A.C. Camargo

Conditions Breast Cancer Cardiotoxicity Heart Failure

Updated 7 times since 2017 Last updated: Jan 31, 2018 Started: Apr 30, 2013 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01724450, this PHASE3 trial focuses on Breast Cancer and Cardiotoxicity and remains completed. Sponsored by Hospital A.C. Camargo, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Mar 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jan 2017 — Mar 2018 [monthly]

Recruiting PHASE3

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital A.C. Camargo
Instituto do Cancer do Estado de São Paulo
University of Sao Paulo

Data source: University of Sao Paulo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil